Dianthus Therapeutics, Inc. (DNTH) Stock Overview
Explore Dianthus Therapeutics, Inc.’s financial performance, market position, analyst ratings, and future outlook.
Dianthus Therapeutics, Inc. (DNTH)
Key Financials
Key Financials
Market Cap
6B
P/E Ratio
-826.04
EPS (TTM)
$-4.15
ROE
-0.04%
DNTH Stock Analysis & Investment Overview (NASDAQ)
Our AI-powered analysis of Dianthus Therapeutics, Inc. (NASDAQ: DNTH) gives investors deep insight into how the stock performs on the NASDAQ exchange, its growth potential, and its market positioning. With a Meyka AI Score of B+, Dianthus Therapeutics, Inc.'s NASDAQ-listed shares demonstrate moderate investment characteristics based on our machine learning models.
The current technical analysis of DNTH on the NASDAQ shows an RSI of 50.26, suggesting the stock is in a a neutral condition. Our forecasting models predict a 12-month price target of $44.69 for the NASDAQ listing.
Key metrics behind Dianthus Therapeutics, Inc.'s NASDAQ-traded stock include a P/E ratio of -826.04 and a market capitalization of 6B. Combined with our AI analysis, these give both institutional and retail investors a clear view of DNTH on the NASDAQ.